ライフサイエンスコーパス: combretastatin A-4

1 cancer cells and superior to colchicine and combretastatin A-4.

2 tereoselective synthesis of anticancer agent combretastatin A-4.

3 arison with the potent colchicine site agent combretastatin A-4.

4 aqueous environments and was as cytotoxic as combretastatin A-4.

5 al products colchicine, podophyllotoxin, and combretastatin A-4.

6 to those of colchicine, podophyllotoxin, and combretastatin A-4.

7 al products colchicine, podophyllotoxin, and combretastatin A-4.

8 al products colchicine, podophyllotoxin, and combretastatin A-4.

9 t, the corresponding carbonate derivative of combretastatin A-4 (13) was unstable in aqueous environm

10 eries of cis- and trans-stilbenes related to combretastatin A-4 (1a), with a variety of substituents

11 ombretum caffrum) antineoplastic constituent combretastatin A-4 (1b) directed at maintaining the (Z)-

12 y crystal structure of the 3'-O-phosphate of combretastatin A-4 (1b) was successfully elucidated.

13 nding of colchicine to tubulin comparable to combretastatin A-4 (1b).

14 sent SAR studies of the antineoplastic agent combretastatin A-4 (1c) were focused mainly on the olefi

15 served with the phosphorylated derivative of combretastatin A-4 (1d), phosphate 3d retained detectabl

16 ombretum caffrum) antineoplastic constituent combretastatin A-4 (3b) led to the discovery of a potent

17 phenolic anticancer drugs etoposide (6) and combretastatin A-4 (7) were attached to the Z-val-cit-p-

18 zole scaffold and designed as cis-restricted combretastatin A-4 analogues, was synthesized with the g

19 nt inhibition of tubulin polymerization than combretastatin A-4 and strong binding to the colchicine

20 mitotic natural products podophyllotoxin and combretastatin A-4 and to that of NSC 664171, a particul

21 embranes, which was similar to cisplatin and combretastatin A-4 and without significant toxicity towa

22 Compounds 9i and j were more active than combretastatin A-4 as inhibitors of tubulin polymerizati

23 rowth and, potentially, to better define the combretastatin A-4 binding site on tubulin.

24 structure of a known microtubule inhibitor, combretastatin A-4, Borowiak et al. develop a photoswitc

25 y-1H-indoles were obtained as a new class of combretastatin A-4 (CA-4) analogues via a convenient ult

26 eric derivatives designed as cis-constrained combretastatin A-4 (CA-4) analogues were synthesized and

27 Cis-stilbene combretastatin A-4 (CA-4) and a large group of its deriv

28 Evidence accumulated with combretastatin A-4 (CA-4) and its prodrug CA-4P support

29 erocycles in place of the cis double bond in combretastatin A-4 (CA-4) are described.

30 Combretastatin A-4 (CA-4) in phosphate and serine pro-dr

31 Combretastatin A-4 (CA-4) is a naturally occurring agent

32 iguration afforded by the cis double bond in combretastatin A-4 (CA-4).

33 embly with IC50 values comparable to that of combretastatin A-4 (CA-4).

34 vel 2,5-diaryl-1,3,4-oxadiazoline analogs of combretastatin A-4 (CA-4, 1) were designed, synthesized,

35 A prodrug of combretastatin A-4 (CA4) was prepared, CMP-L-CA4, where

36 ed photosensitizer, a chemo-prodrug based on combretastatin A-4 (CA4) with a singlet oxygen-cleavable

37 inoacrylate linker (L), and a cytotoxic drug combretastatin A-4 (CA4).

38 ion from the natural products colchicine and combretastatin A-4 (CA4).

39 The mechanism of combretastatin A-4 cytotoxicity has now been investigate

40 Incubation of cells for up to 8 h with combretastatin A-4 did not induce the release of lactate

41 The antiangiogenic, tubulin-binding drug combretastatin A-4 exhibits a selective toxicity for pro

42 was detected in cells incubated with 0.1 mM combretastatin A-4 for 24 h.

43 totoxic and antitubulin activity compared to combretastatin A-4 in neuroblastoma cells, showing a bet

44 n was confirmed, and it was more potent than combretastatin A-4 in these assays.

45 Incubation of cells with 0.1 mM combretastatin A-4 induced the conversion (first detecte

46 icate that the selective cytotoxic effect of combretastatin A-4 is mediated by the induction of apopt

47 tected with either the colchicine site agent combretastatin A-4 or with an analog of the antimitotic

48 and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain

49 Combretastatin A-4 phosphate (CA4P) is a microtubule-dis

50 Combretastatin A-4 phosphate (CA4P) is a novel antitumor

51 matosis (PC) and breast cancer mice with VDA combretastatin A-4 phosphate (CA4P) resulted in upregula

52 Purpose To determine if combretastatin A-4 phosphate disodium (CA4P) can enhance

53 nd is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived

54 del comparable to the activity obtained with combretastatin A-4 phosphate.

55 Combretastatin A-4-phosphate (CA-4-P) is a tubulin-bindi

56 The tubulin-binding agent combretastatin A-4-phosphate (CA-4-P), rapidly disrupts

57 In this study the effect of a CA-4 prodrug, combretastatin A-4-phosphate (CA-4-P), was tested in two

58 Compound 1b has been termed the "combretastatin A-4 prodrug", and it is currently undergo

59 This benzophenone derivative of combretastatin A-4 showed remarkable antineoplastic acti

60 expectedly obtained by Jacobsen oxidation of combretastatin A-4 silyl ether (1c --> 3a), and the pare

61 ture of the tubulin polymerization inhibitor combretastatin A-4, the possibility exists that the rati

62 The geometric trans-isomer 3a of combretastatin A-4 was converted to the (1S,2S)- and (1R

63 ion (IC50 = 22 microM, versus 1.2 microM for combretastatin A-4), while 4d was inactive (IC50 > 40 mi